Breaking News

Quotient Sciences, Intrepid Labs Partner to Advance AI in Early Drug Development

Quotient Sciences gains access to Intrepid’s machine learning model, ANDROMEDA, an AI platform designed to develop and optimize clinical performance of drug products.

Author Image

By: Charlie Sternberg

Associate Editor

Quotient Sciences, a global drug development, research and manufacturing accelerator, and Intrepid Labs, an AI leader in pharmaceutical formulation science, have announced a multi-year strategic partnership to advance the use of artificial intelligence (AI) in early drug development. Read Contract Pharma’s Exclusive Interview with Quotient and Intrepid Leadership About the Partnership Under the new agreement, Quotient Sciences will have access to Intrepid’s machine learning mode...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters